Porfiromycin
Head and Neck Neoplasms
Boehringer IngelheimPhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
23 Active assets in the Head and Neck Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Rutgers, The State University of New Jersey | Phase 4 | BB |
Pembrolizumab Mayo Clinic | Phase 3 | BB |
Cyclophosphamide M.D. Anderson Cancer Center | Phase 3 | BB |
Capecitabine Rutgers, The State University of New Jersey | Phase 4 | B |
Pralsetinib, trans- Hoffmann-La Roche | Phase 3 | B |
View all 44 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →